943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SCW. Sandborn, P. J. Rutgeerts, C. W. Marano et al.|Gastroenterology|2012Cited by 27